Agios Pharmaceuticals, Inc. (AGIO) — Analyst outlook / Analyst consensus target is. Based on 29 analyst ratings, the consensus is bullish — 22 Buy, 7 Hold.
The consensus price target is $41.50 (low: $25.00, high: $62.00), representing an upside of 24.6% from the current price $33.30.
Analysts estimate Earnings Per Share (EPS) of $11.44 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $11.86 vs est $11.44 (beat +3.7%). 2025: actual $-7.12 vs est $-7.06 (missed -0.8%). Analyst accuracy: 98%.
AGIO Stock — 12-Month Price Forecast
$41.50
▲ +24.62% Upside
Average Price Target
Based on 29 Wall Street analysts offering 12-month price targets for Agios Pharmaceuticals, Inc., the average price target is $41.50, with a high forecast of $62.00, and a low forecast of $25.00.
The average price target represents a +24.62% change from the last price of $33.30.
Highest Price Target
$62.00
Average Price Target
$41.50
Lowest Price Target
$25.00
AGIO Analyst Ratings
Buy
Based on 29 analysts giving stock ratings to Agios Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — AGIO
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $11.86
vs Est $11.44
▲ 3.5% off
2025
Actual –$7.12
vs Est –$7.06
▼ 0.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — AGIO
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.036B
vs Est $0.035B
▲ 3.7% off
2025
Actual $0.054B
vs Est $0.046B
▲ 14.6% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
